Original Article

Prevalence of Restless Legs Syndrome in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Mehrdad Bagherpour-kalo[1], Parvaneh darabi[2], Ali Moghadas Jafari[3], Hamid Najafimehr[4], Kamal Azam[1*], Mostafa Hosseini[1*]

[1]Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences Tehran, Iran.
[2]Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
[3]Farhikhtegan Hospital, Azad University of Medical Sciences, Tehran, Iran.
[4]Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.

ARTICLE INFO

ABSTRACT

Introduction: Restless legs syndrome (RLS) is a common sensorimotor sleep disorder, and rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes disability. Previous studies showed that the prevalence of RLS varies in different populations of RA (13.2 – 68.4%). It raises the need for a pooled meta-analysis to determine a more reliable estimate. Therefore, we aimed to perform a meta-analysis to assess the pooled prevalence of RLS in RA patients.

Methods: Meta-analysis was performed according to the PRISMA checklist. Embase, MEDLINE, Ovid, Web-of-Science, and Scopus databases were used for the systematic search, and eligible studies were analyzed using R version 4.0.3. For further review, we performed sensitivity analyzes to identify influential studies.

Results: Of a total of 763 studies, 11 studies (3 were from Europe, 4 from North America, and 4 from Asia) were suitable for synthesis. A total of 931 RA patients were identified, 300 of whom had symptoms of RLS. The pooled prevalence of RLS among people with RA from 11 studies was 34% (95% CI: 26-43%). The pooled prevalence of RLS in Europe, Asia, and North America was 48% (95% CI: 32-65%), 32% (95% CI: 18-45%), and 28% (95% CI: 15-42%), respectively. RLS prevalence was dramatically high in RA women patients (32% CI: 23-41%) than RA men patients (3%; 95% CI: 2-5%).

Conclusion: This systematic review and meta-analysis indicates that the risk of RLS in RA patients was 34% and female patients with RA were more prone to having RLS than male patients.

Introduction

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a common sensorimotor sleep disorder whose main feature is the urge to move the legs.[1] Previous literature has extensively discussed the epidemiology of RLS.[2-4] In summary, symptoms worsen with inactivity or rest (especially in the evening or at night). Increasing movement relieves the symptoms partly (or totally). RLS has a prevalence rate of 5-15% in the general

---

population, is more common in women, and is associated with conditions such as Parkinson's disease, renal failure, diabetes mellitus, headaches, pregnancy, hypertension, and rheumatoid arthritis (RA). RLS also has significant interaction with the overall aspect of the immune system.[5]

RA is an inflammatory autoimmune disease that causes disability. It typically results in warmth, swelling, muscle wasting, joint involvement, and painful joints.[6] In addition, women are at least 2 times more likely to be affected by RA than men.[6, 7] As of 2015, RA had caused 3,000 deaths[8] and affected 24.5[9] million people worldwide. The cause of RA is unknown, but SOKKA et al. have suggested that inactivity may be an influential factor in the prevalence of RA, which was traditionally known as a treatment to improve rheumatic diseases.[10] Therefore, the association between RLS and RA could probably be explained by the changes in immunomodulation and inactivity in patients.

In the last two decades, several studies have reported the prevalence of RLS in people with RA based on different RLS diagnostic criteria (questionnaire and clinical criteria).[11-21] From these studies, the prevalence of RLS varies in different populations of RA (13.2 – 68.4%). It raises the need for a pooled meta-analysis to determine a more reliable estimate. Therefore, we performed a meta-analysis to assess the pooled prevalence of RLS in RA patients.

Materials and Methods

This meta-analysis was performed according to the PRISMA checklist (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).[22]

Search strategy

The five databases (Embase, PubMed, Ovid, Web-of-Science, and Scopus) were systematically searched for the search terms "restless legs syndrome" and "rheumatoid arthritis" through February 2022. The search was limited to humans, with no restrictions on age, date, or language.

Include and exclude criteria

The inclusion criteria for the present meta-analysis were: RLS occurred after the prevalence of RA, it had to be possible to calculate the prevalence of RLS in RA patients, RLS had to be diagnosed by a standard method (questionnaires, clinical criteria, or clinical interviews), and studies had to be observational.

Exclusion criteria included: RA patients without RLS symptoms or vice versa; unrelated publication type (such as letter, correspondence, review, editorial, etc.); incomplete data or inability to calculate the prevalence of RLS in RA patients; diagnosed RLS before diagnosis RA.

Data collection

Two authors (M. Bagherpour-Kalo and P. Darabi) conducted the literature search independently and extracted the data. Disagreements were resolved by a third author (M. Hosseini). First author name, year of publication, country, method of RLS diagnosis, sample size, age of RA patients, number of RA patients with and without RLS, number of RLS and RA by sex, and prevalence of RLS in RA patients.

Statistical analysis

The prevalence of RLS in patients with RA was evaluated by sex and continent using the metafor and meta packages in R version 4.0.3 (https://www.r-project.org). In all analysis, a p-value of less than 0.05 is considered a significant threshold.

We use the Q-test and the I^2 index to assess heterogeneity and homogeneity. The Q-test is used to identify heterogeneity, and I^2 is a good index to identify the quantified homogeneity of studies. Heterogeneity was considered as homogeneity ($I^2 < 25$), low heterogeneity ($25\% \leq I^2 < 50\%$), moderate heterogeneity ($50\% \leq I^2 < 75\%$), and substantial heterogeneity ($I^2 \geq 75\%$)(23). Identifying heterogeneity helps us to use appropriate models ($I^2 < 50\%$:fixed-effect; $I^2 \geq 75\%$: random-effect) to determine the pooled analysis.[24] Forest plots were used to visually represent the results. We also used Begg's regression test (statistical) and funnel plot (visual) to assess publication bias,[25] and sensitivity analysis was performed by leaving out of each study.

To evaluate the robustness of our findings, we conducted a sensitivity analysis using several methods. We used the leaving out method and Cook's distance to identify any studies that had a particularly strong influence on the results. We also used standardized residuals and other criteria, which are presented in the supplementary file, to check for outliers. After identifying any outliers or influential studies, we refitted the model by leaving them out one at a time to determine the robustness of our results.

Results
Study characteristics

After removing duplicates, a total of 607 unique studies were identified. Of these, 596 studies did not meet all inclusion criteria and were excluded from the meta-analysis (Figure 1). Of the 11 remaining eligible studies,[11-21] 3 were from Europe, 4 from North America, and 4 from Asia. A total of 931 RA patients were identified, 300 of whom had symptoms of RLS (Table 1). Seven studies diagnosed RLS according to International RLS Study Group (IRLSSG) criteria, and 4 studies used other diagnostic methods. Six studies (599 participants) reported prevalence by sex. Only one or two studies provided information on factors associated with RLS (including age, laboratory indices, family history, etc.). Therefore, no meta-analysis was performed for these factors.

Prevalence of RLS in RA patients

Because of the high heterogeneity ($I^2 = 87\%$, P < 0.01) among studies, we used a random-effect model based on DerSimonian and Laird method. The result showed that the pooled prevalence of RLS among people with RA from 11 studies was 34% (95% CI: 26-43%; Figure 2).

The funnel plot and Begg's test suggested a significant publication bias in the meta-analysis (Kendall's tau = 0.49, P = 0.040; Figure 3).

The sensitivity analysis showed that two of the studies[3, 15] affected results (Supplementary Figure S1 and Figure S2). When we excluded these two studies, the pooled prevalence of RLS was 29% (95% CI: 22-36%; Supplementary Figure S3).

Figure 1. Flow diagram of selecting eligible studies.

Subgroup analysis

Although we found differences in geographical areas in the prevalence of RLS in RA patients, it was not significant (χ^2 = 3.72, df = 2; P = 0.16). The pooled prevalence of RLS in Europe, Asia, and North America was 48% (95% CI: 32-65%; Supplementary Figure S4), 32% (95% CI: 18-45%; Supplementary Figure S4), and 28% (95% CI: 15-42%; Supplementary Figure S4), respectively.

There were differences in RLS's diagnosis method in the prevalence of RLS among people with RA, but it also was not significant (χ^2 = 0.60, df = 1; P = 0.44). The pooled prevalence with the IRLSSG method was 32% (95% CI: 21-43%; Supplementary Figure S5), and another diagnostic method was 39% (95% CI: 25-54%; Supplementary Figure S5).

A significant sex difference was observed in the meta-analysis, which had a very high prevalence in females (χ^2 = 38.01, df = 1; P < 0.01). In female patients, the pooled prevalence in Europe, Asia, and North America was 44% (95% CI: 33-56%; Figure 4), 25% (95% CI: 20-29%; Figure 4), and 24% (95% CI: 11-37%; Figure 4), respectively, and in male patients, the pooled prevalence in Europe, Asia, and North America was 8% (95% CI: 3-13%; Figure 5), 2% (95% CI: 1-4%; Figure 5), and 5% (95% CI: 0-11%; Figure 5), respectively.

Discussion

In the present study, due to high heterogeneity,

Table 1. Characteristics of the eligible studies.

Study	Country	Diagnosis Method	Sample Size	RLS	Male with RLS	Female with RLS	Male with RA	Female with RA	Prevalence	Ref.
Reynolds (1986)	British	Standard questionnaire	70	21	0	21	10	60	30%	(16)
Salih (1994)	British	Gibb and Lees criteria	87	46	8	38	16	25	52.87%	(17)
Hirsch (1994)	France	Clinical Assessment: duration of morning stiffness (in minutes), number of nocturnal awakenings, number of tender joints, number of swollen joints, Ritchie articular index, and Lee functional index	19	13	1	12	1	18	68.42%	(13)
Yunus (1996)	USA	Standardized questionnaire	54	8	0	8	0	54	14.82%	(21)
Auger (2005)	Canada	Questionnaire based on the IRLSSG criteria.	100	31	NR	NR	35	65	31%	(11)
Regina (2009)	Canada	Questionnaire based on the IRLSSG criteria.	148	41	NR	NR	NR	NR	27.8%	(5)
Ishaq (2013)	Pakistan	Questionnaire based on the IRLSSG criteria.	240	65	5	60	NR	NR	27.08%	(14)
Regina (2014)	Canada	Questionnaire based on the IRLSSG criteria and Physical Activity Monitor	57	23	3	20	9	48	40.35%	(18)
Mustafa (2019)	Saudi Arabia	Questionnaire based on the IRLSSG criteria.	41	26	NR	NR	5	96	63.41%	(15)
Urashima (2020)	Japan	Questionnaire based on the IRLSSG criteria.	43	5	NR	NR	NR	NR	11.63%	(20)
Demir (2021)	Turkey	Questionnaire based on the IRLSSG criteria.	72	21	4	17	13	59	29.17%	(12)

RLS, Restless Legs Syndrome; RA, Rheumatoid Arthritis; IRLSSG, International RLS Study Group


Figure 2. Forest plot of the prevalence of RLS in RA patients.

Figure 3. Funnel plot for 11 eligible studies include in meta-analysis.

Figure 4. Forest plot of pooled prevalence of RLS in female RA patients.

Figure 5. Forest plot of pooled prevalence of RLS in male RA patients.

we used a random-effect model to conduct the meta-analysis in 931 rheumatoid arthritis patients, of whom 300 had symptoms of restless legs syndrome.

According to 11 eligible studies, the pooled prevalence of RLS in RA patients was 34% and varied across different geographical areas (the prevalence of RLS among RA patients in Europe was relatively high) and diagnostic methods (the prevalence of RLS among RA patients using the IRLSSG method was low). One problem that clinicians struggle with is that RLS patients do not visit rheumatology centers out of ignorance. Therefore, the exact cause and pathogenesis of RLS in rheumatoid patients had unknown for many years. For example, Ondo et al., showed in a population of 68 RLS patients that showed that RA does not play a significant role in the pathogenesis

of RLS patients.[26]
In the past two decades, efforts have been made to identify risk factors for RLS in RA patients. As a result, fatigue,[12] total iron binding capacity,[12] serum ferritin,[15, 17] sleep quality,[27] periodic limb movements,[18] and hemoglobin[7] were identified as influencing factors. In another study, Taylor-Gjevre et al. examined the sleep parameters of 12 individuals with RA and found that sleep efficiency could be improved by antitumor necrosis factor alpha therapy.[28] Thus, clinicians consider neuropathies to be an important factor in the development of RLS in RA patients.
This meta-analysis also found that an important factor affecting the prevalence of RLS in RA patient was gender. Compared with men, RLS prevalence was dramatically high in RA women patients (P<0.01). It

confirms the findings of previous studies. Berger et al.[29] and Smolen et al.[30] showed that RLS prevalence and RA prevalence were at least twice as high in women in the general population. Therefore, a dominant role of sex hormones could be suspected as the main cause of sex differences. Combining three genome-wide association studies from 2003 to 2017, Schormair et al. showed that MEIS1 is a strong genetic risk factor for RLS.[31] Because MEIS1 interacts with estrogen receptors,[32] this may raise a hypothesis for its differential involvement in RA patients with RLS.

A subgroup analysis showed that RA patients in Europe were more likely to have RLS compared with other geographic areas. The difference could be due to genetics, environment, lifestyle, or race. The previous study aimed to evaluate the association between lifestyle factors and the risk of RLS, suggested that obesity, physical activity, or smoking affect RLS prevalence.

Two strengths of this systematic review and meta-analysis included the following. First, to our knowledge, this is the first study applying meta-analysis to evaluate overall RLS prevalence in RA patients. Second, using sensitivity analysis to reduce the risk of bias and identify influential studies.

This meta-analysis included two limitations. First, few studies have shown the effect of risk factors (such as age, body mass index, and family history) on RLS prevalence among RA patients. The positive and significant impact of these factors on RLS has been shown in previous studies.[29] Accordingly, body mass index (above 30) and family history were seen in at least 28.5%[29] and 50%[33] of RLS patients, respectively. Forasmuch as some other characteristics such as the age of onset, treatment and therapies, and sleep quality were not included in the present meta-analysis. Therefore, evaluate of RLS risk factors in RA patients who suffer from RLS is emphasized. Second, the pooled estimate was affected by publication bias. Therefore, more research is required to examine the variation in detail.

Conclusion

This study indicates that the risk of RLS in RA patients was 34% and female patients with RA were more prone to having RLS than male patients. The pooled analysis provides a reliable estimate of the prevalence of RLS among RA patients. Further studies are needed to understand the association between RA and RLS and clarify the role of various factors among different populations.

Abbreviations

RLS, Restless Legs Syndrome; RA, Rheumatoid Arthritis; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses, IRLSSG, International RLS Study Group;

Authors' contributions

Investigation: MH, MBK, PD;
Pre-processing and conduct analyzes: MBK;
Frame work of paper: MH, MBK, PD;
Writing: MH, MBK, PD;
Approval of manuscript: MH, MBK, PD.

Funding

None.

Competing interests

The authors declare that they have no competing interests.

References

1.   Manconi M, Garcia-Borreguero D, Schormair B, Videnovic A, Berger K, Ferri R, et al. Restless legs syndrome. Nature Reviews Disease Primers. 2021;7(1):80.

2.   Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. The Lancet Neurology. 2005;4(8):465-75.

3.   Yeh P, Walters AS, Tsuang JW. Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep and Breathing. 2012;16(4):987-1007.

4.   Ekbom K, Ulfberg J. Restless legs syndrome. Journal of Internal Medicine. 2009;266(5):419-31.

5.   Taylor-Gjevre RM, Gjevre JA, Skomro R, Nair B. Restless legs syndrome in a rheumatoid arthritis patient cohort. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2009;15(1):12-5.

6.   Majithia V, Geraci SA. Rheumatoid Arthritis: Diagnosis and Management. The American Journal of Medicine. 2007;120(11):936-9.

7.   Gabriel SE. The epidemiology of rheumatoid arthritis. Rheumatic disease clinics of north America. 2001;27(2):269-81.

8.   Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1459-544.

9.   Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388(10053):1545-602.

10.   Sokka T, Häkkinen A, Kautiainen H, Maillefert JF, Toloza S, MØrk hansen T, et al. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2008;59(1):42-50.

11.   Auger C, Montplaisir J, Duquette P. Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology. 2005;65(10):1652-3.

12.   Demir S, Kucuk A, Altas M, Cure E. Restless Leg Syndrome and Sleep Disorders in Patients with Rheumatoid Arthritis and Its Relation with Anemia Parameters. ACTA MEDICA. 2021;64(3):137-44.

13.   Hirsch M, Carlander B, Vergé M, Tafti M, Anaya JM, Billiard M, et al. Objective and subjective sleep disturbances in patients with rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of

Rheumatology. 1994;37(1):41-9.

14. Ishaq M, Sualeh Muhammad J, Hameed K. Risk of restless legs syndrome in low socioeconomic rheumatoid arthritis patients. Modern rheumatology. 2013;23(4):705-8.

15. Mustafa M, Bawazir Y, Merdad L, Wali S, Attar S, Fathaldin O, et al. Frequency of sleep disorders in patients with rheumatoid arthritis. Open Access Rheumatology: Research and Reviews. 2019;11:163.

16. Reynolds G, Blake D, Pall H, Williams A. Restless leg syndrome and rheumatoid arthritis. British Medical Journal (Clinical research ed). 1986;292(6521):659.

17. Salih A, Gray R, Mills K, Webley M. A clinical, serological and neurophysiological study of restless legs syndrome in rheumatoid arthritis. Rheumatology. 1994;33(1):60-3.

18. Taylor-Gjevre RM, Gjevre JA, Nair BV. Increased nocturnal periodic limb movements in rheumatoid arthritis patients meeting questionnaire diagnostic criteria for restless legs syndrome. BMC Musculoskeletal Disorders. 2014;15(1):1-5.

19. Taylor-Gjevre RM, Gjevre JA, Skomro R, Nair B. Restless legs syndrome in a rheumatoid arthritis patient cohort. JCR: Journal of Clinical Rheumatology. 2009;15(1):12-5.

20. Urashima K, Ichinose K, Kondo H, Maeda T, Kawakami A, Ozawa H. The prevalence of insomnia and restless legs syndrome among Japanese outpatients with

rheumatic disease: a cross-sectional study. PloS one. 2020;15(3):e0230273.

21. Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. Bmj. 1996;312(7042):1339.

22. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine. 2009;6(7):e1000097.

23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557-60.

24. Zhang T, Zhong W, Li B. Applied methodology for evidence-based medicine. Press of Central South University. 2011.

25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.

26. Ondo W, Tan EK, Mansoor J. Rheumatologic serologies in secondary restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2000;15(2):321-3.

27. Taylor-Gjevre R, Gjevre J, Nair B, Skomro R, Lim H. Components of sleep quality and sleep fragmentation in rheumatoid arthritis and osteoarthritis. Musculoskeletal care. 2011;9(3):152-9.

28. Taylor-Gjevre RM, Gjevre JA,

Skomro RP, Nair BV, Lim HJ. Improved sleep efficiency after anti-tumor necrosis factor α therapy in rheumatoid arthritis patients. Therapeutic advances in musculoskeletal disease. 2011;3(5):227-33.

29.　　Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Archives of internal medicine. 2004;164(2):196-202.

30.　　Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet (London, England). 2016;388(10055):2023-38.

31.　　Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B, et al. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. The Lancet Neurology. 2017;16(11):898-907.

32.　　Wang Y, Xie X, Zhang C, Su M, Gao S, Wang J, et al. Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood. Annals of the rheumatic diseases. 2022;81(3):379-85.

33.　　Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lespérance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Movement disorders: official journal of the Movement Disorder Society. 1997;12(1):61-5.

Supplementary Material

Table S1. PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	-
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3-4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	3-4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	3
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	-

Prevalence of Restless Legs Syndrome in Rheumatoid Arthritis ...

Section/topic	#	Checklist item	Reported on page #
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	4
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	4
Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	-
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	4, Appendix A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	4
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	4, Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	-
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	5, Fig 2, Fig 4, Fig 5, Fig S3, Fig S4, Fig S5
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	5, Fig 2, Fig 4, Fig 5, Fig S3, Fig S4, Fig S5
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Appendix A, Fig S1, Fig S2
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	Fig 4, Fig 5, Appendix A, Fig S1, Fig S2, Fig S3, Fig S4, Fig S5
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	5-6
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	6
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	6
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	6

Appendix A: Sensitivity analysis

Figure S1. Suggests that the exclusion of two studies (Salih, 1994; Hirsch, 1994; Mustafa, 2019) has a significant effect on the magnitude of the results. For a more detailed examination, 8 criteria (including cook distant, residuals, and adjusted difference) were used to examine the results of the studies (identification of outlier results) (see Figure S2). The result showed that two studies (Hirsch, 1994 and Mustafa, 2019) had an impact on the results. After excluding these two studies, the combined analysis showed a prevalence of RLS of 29% in RA patients. More details are provided in Figure S3.

Study	Proportion [95% CI]
Reynolds et al. (1986)	0.35 [0.26, 0.44]
Salih et al. (1994)	0.32 [0.24, 0.40]
Hirsch et al. (1994)	0.32 [0.24, 0.40]
Yunus et al. (1996)	0.37 [0.28, 0.45]
Auger et al. (2005)	0.35 [0.26, 0.44]
Regina et al. (2009)	0.35 [0.26, 0.45]
Ishaq et al. (2013)	0.36 [0.26, 0.46]
Regina et al. (2014)	0.34 [0.25, 0.43]
Mustafa et al. (2019)	0.32 [0.24, 0.39]
Urashima et al. (2020)	0.37 [0.28, 0.45]
Salih Demir et al. (2021)	0.35 [0.26, 0.44]

Summary proportions leaving out each study

Figure S1. Leaving out each study

Figure S2. Sensitive analysis to identify outlier results

Study (year)	RLS	N	Proportion	95% C.I.	Weight (common)	Weight (random)
Reynolds et al. (1986)	21	70	0.30	[0.19; 0.41]	7.3%	10.5%
Salih et al. (1994)	46	87	0.53	[0.42; 0.63]	7.7%	10.7%
Yunus et al. (1996)	8	54	0.15	[0.05; 0.24]	9.4%	11.1%
Auger et al. (2005)	31	100	0.31	[0.22; 0.40]	10.3%	11.3%
Regina et al. (2009)	41	148	0.28	[0.20; 0.35]	16.3%	12.2%
Ishaq et al. (2013)	65	240	0.27	[0.21; 0.33]	26.8%	12.8%
Regina et al. (2014)	23	57	0.40	[0.28; 0.53]	5.2%	9.6%
Urashima et al. (2020)	5	43	0.12	[0.02; 0.21]	9.2%	11.1%
Salih Demir et al. (2021)	21	72	0.29	[0.19; 0.40]	7.7%	10.7%
Pooled Fixed Effect Model		.	**0.28**	**[0.25; 0.31]**	**100.0%**	--
Pooled Random Effect Model			**0.29**	**[0.22; 0.36]**	--	**100.0%**

Heterogeneity: $I^2 = 82\%$, $\tau^2 = 0.0094$, $\chi^2_8 = 44.58$ ($p < 0.01$)

0   0.2   0.4   0.6   0.8   1
Prevalence of RLS in RA patients

Figure S3. Forest plot of the prevalence of RLS in RA patients after removing outlier results

Study	RLS	N	Proportion	95% C.I.	Weight (common)	Weight (random)
Continent = Europe						
Reynolds et al. (1986)	21	70	0.30	[0.19; 0.41]	6.9%	9.2%
Salih et al. (1994)	46	87	0.53	[0.42; 0.63]	7.3%	9.3%
Hirsch et al. (1994)	13	19	0.68	[0.48; 0.89]	1.8%	6.4%
Fixed Effect		.	**0.45**	**[0.38; 0.52]**	16.0%	--
Random Effect Model			**0.48**	**[0.32; 0.65]**	--	24.9%
Heterogeneity: $I^2 = 86\%$, $\tau^2 = 0.0165$, $\chi^2_2 = 14.48$ ($p < 0.01$)						
Continent = North– America						
Yunus et al. (1996)	8	54	0.15	[0.05; 0.24]	8.9%	9.5%
Auger et al. (2005)	31	100	0.31	[0.22; 0.40]	9.7%	9.6%
Regina et al. (2009)	41	148	0.28	[0.20; 0.35]	15.4%	10.0%
Regina et al. (2014)	23	57	0.40	[0.28; 0.53]	4.9%	8.7%
Fixed Effect		.	**0.27**	**[0.23; 0.32]**	39.0%	--
Random Effect Model			**0.28**	**[0.15; 0.42]**	--	37.9%
Heterogeneity: $I^2 = 74\%$, $\tau^2 = 0.0165$, $\chi^2_3 = 11.35$ ($p < 0.01$)						
Continent = Asia						
Ishaq et al. (2013)	65	240	0.27	[0.21; 0.33]	25.3%	10.4%
Mustafa et al. (2019)	26	41	0.63	[0.49; 0.78]	3.7%	8.1%
Urashima et al. (2020)	5	43	0.12	[0.02; 0.21]	8.7%	9.5%
Salih Demir et al. (2021)	21	72	0.29	[0.19; 0.40]	7.3%	9.3%
Fixed Effect		.	**0.27**	**[0.23; 0.32]**	45.0%	--
Random Effect Model			**0.32**	**[0.18; 0.45]**	--	37.2%
Heterogeneity: $I^2 = 91\%$, $\tau^2 = 0.0165$, $\chi^2_3 = 33.45$ ($p < 0.01$)						
Pooled Fixed Effect Model		.	**0.30**	**[0.27; 0.33]**	**100.0%**	--
Pooled Random Effect Model			**0.34**	**[0.26; 0.43]**	--	**100.0%**

0   0.2   0.4   0.6   0.8   1
Prevalence of RLS in RA patients

Heterogeneity: $I^2 = 87\%$, $\tau^2 = 0.0166$, $\chi^2_{10} = 79.00$ ($p < 0.01$)
Residual heterogeneity: $I^2 = 87\%$, $\tau^2 = 0.0165$, $\chi^2_8 = 59.29$ ($p < 0.01$)
Test for subgroup differences (common effect): $\chi^2_2 = 19.71$, df = 2 ($p < 0.01$)
Test for subgroup differences (random effects): $\chi^2_2 = 3.72$, df = 2 ($p = 0.16$)

Figure S4. Prevalence of RLS in RA patients in different geographical areas

Prevalence of Restless Legs Syndrome in Rheumatoid Arthritis ...

| Study	RLS	N	Proportion	95% C.I.	Weight (common)	Weight (random)
group = Identification of RLS using the IRLSSG criteria						
Auger et al. (2005)	31	100	0.31	[0.22; 0.40]	9.7%	9.6%
Regina et al. (2009)	41	148	0.28	[0.20; 0.35]	15.4%	10.0%
Ishaq et al. (2013)	65	240	0.27	[0.21; 0.33]	25.3%	10.4%
Regina et al. (2014)	23	57	0.40	[0.28; 0.53]	4.9%	8.7%
Mustafa et al. (2019)	26	41	0.63	[0.49; 0.78]	3.7%	8.1%
Urashima et al. (2020)	5	43	0.12	[0.02; 0.21]	8.7%	9.5%
Salih Demir et al. (2021)	21	72	0.29	[0.19; 0.40]	7.3%	9.3%
Fixed Effect		.	0.29	[0.26; 0.32]	75.0%	--
Random Effect Model			0.32	[0.21; 0.43]	--	65.6%
Heterogeneity: $I^2 = 84\%$, $\tau^2 = 0.0182$, $\chi^2_6 = 37.35$ ($p < 0.01$)						
group = Identification of RLS using the other criteria						
Reynolds et al. (1986)	21	70	0.30	[0.19; 0.41]	6.9%	9.2%
Salih et al. (1994)	46	87	0.53	[0.42; 0.63]	7.3%	9.3%
Hirsch et al. (1994)	13	19	0.68	[0.48; 0.89]	1.8%	6.4%
Yunus et al. (1996)	8	54	0.15	[0.05; 0.24]	8.9%	9.5%
Fixed Effect		.	0.34	[0.28; 0.40]	25.0%	--
Random Effect Model			0.39	[0.25; 0.54]	--	34.4%
Heterogeneity: $I^2 = 92\%$, $\tau^2 = 0.0182$, $\chi^2_3 = 39.14$ ($p < 0.01$)						
Pooled Fixed Effect Model		.	**0.30**	**[0.27; 0.33]**	**100.0%**	--
Pooled Random Effect Model			**0.34**	**[0.26; 0.43]**	--	**100.0%**

Prevalence of RLS in RA patients

Heterogeneity: $I^2 = 87\%$, $\tau^2 = 0.0166$, $\chi^2_{10} = 79.00$ ($p < 0.01$)
Residual heterogeneity: $I^2 = 88\%$, $\tau^2 = 0.0182$, $\chi^2_9 = 76.49$ ($p < 0.01$)
Test for subgroup differences (common effect): $\chi^2_1 = 2.51$, df = 1 ($p = 0.11$)
Test for subgroup differences (random effects): $\chi^2_1 = 0.60$, df = 1 ($p = 0.44$)

Figure S5. Prevalence of RLS in RA patients in different identification criteria